Affymax, Takeda update Hematide strategy

Affymax Inc. (NASDAQ:AFFY) gained $1.70 (26%) to $8.13 on Thursday after it and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) announced tentative plans to submit an NDA for Hematide peginesatide to treat anemia in dialysis patients in 1H11. The timeline will be finalized following a meeting with FDA that is expected to be held by year end. The partners will continue to evaluate the synthetic peptide-based erythropoiesis-stimulating agent (ESA) in non-dialysis patients. ...